Permira vs Vitruvian Partners

Brian Ruder joined Dani Burger on Bloomberg Deals to talk about where we are in the cycle

Permira Co-CEO Brian Ruder appeared on Bloomberg Deals to discuss the current market cycle and implications for private equity investors. Also new: AI & Customer Experience | Kleinanzeigen.

Golden Goose Reports Double-Digit Growth, Expands DTC

Italian luxury fashion brand Golden Goose reported a 15% currency-adjusted revenue increase to €380.4 million in H1 2026, with Q2 growth accelerating to 19%. Direct-to-consumer (DTC) sales surged 22% to €309.6 million, representing 81% of total revenue, up from 77% a year earlier. All regions saw double-digit growth, with the Americas up 18%, EMEA 14%, and APAC 17%. Adjusted EBITDA rose 9% to €122.9 million, with a 32.3% margin. The company opened new stores, including locations in Athens and Rome, and launched its first Younique Caffè in Europe. During Q2, ownership changed with HSG becoming majority shareholder, Temasek investing as a minority, and Permira remaining a strategic shareholder, aiming to support international expansion and innovation.

• H1 2026 revenue increased 15% to €380.4 million
• DTC revenue up 22% to €309.6 million (81% of total revenue)
• Adjusted EBITDA rose 9% to €122.9 million in H1 2026

Permira Appoints Former Microsoft Executive Julia Liuson as Senior Adviser

Permira announces the appointment of Julia Liuson, former Microsoft executive, as Senior Adviser. Also, JTC enters new growth phase in partnership with Permira, and Seismic completes merger with Highspot.

Angle Health raises $600M at $2.7B valuation

Health insurance startup Angle Health announced a $200 million Series C round and a $400 million tender offer, giving the company a $2.7 billion valuation. The round was led by Vitruvian Partners with participation from Town Hall Ventures, Blumberg Capital, Portage Ventures, PruVen Capital, and Y Combinator. The tender offer permits employees to cash out shares, and the transaction is expected to close later this month. Angle Health, a Winter 2020 Y Combinator alum, helps small businesses manage level-funded health plans, offering a middle ground between fully insured and self-funded options. The company's AI-powered platform integrates with payroll and HR systems, serves over 5,000 businesses, and is reportedly profitable. This funding round is notable as it comes from a non-AI-agent startup founded in 2019.

• Angle Health raised a $200 million Series C round.
• The funding round included a $400 million tender offer.
• The company's valuation is now $2.7 billion.

DeepIntent launches agentic ad platform Cora for pharma marketing

DeepIntent, a healthcare-focused adtech firm, has launched Cora, an AI-powered agentic advertising platform designed for pharmaceutical marketers. The platform uses multiple AI agents to handle campaign planning, audience strategy, and media execution, including linear TV via a VideoAmp integration. Cora aims to speed up marketing workflows, with beta tests showing a 50% reduction in planning cycles and over 95% of clients reporting faster processes. This launch follows DeepIntent's majority stake sale to Vitruvian Partners, which provided $637 million to develop AI tools. The company targets the growing complexity of pharma marketing, especially for niche drugs targeting small patient populations. Cora is also powered by Helix, a data application providing aggregated healthcare data, including payer signals and drug coverage insights.

• DeepIntent launched Cora, an agentic ad platform for pharma marketing.
• Cora uses AI agents for campaign planning, audience targeting, and execution.
• Cora integrates with VideoAmp for linear TV campaign execution.